Technology Bundle ID

Antagonists of Hyaluronan Signaling for Treatment of Airway Diseases

Linked ID
Lead Inventors
Stavros Garantziotis (NIEHS)
Bryan Toole (Medical University of South Carolina)
Jian Liu (University of North Carolina - Chapel Hill)
John Hollingsworth (Duke University Medical Center)
Development Stages
Pre-clinical (in vivo)
Development Status
In vitro data available
Airway diseases, such as Asthma and Chronic Obstructive Pulmonary Disease (COPD), constitute a major health burden worldwide. It is estimated, for example, that nearly 15.0% of the adult population in the US are affected with such diseases, and the economic cost burden is over $23 billion annually. Unfortunately, the current options for treatment of such diseases are quite limited, consisting only of bronchodilators and inhaled steroids. The need for a novel and more effective class of therapeutics agents is imperative. The subject invention provides for a potentially more specific and effective treatment of airway diseases as compared with existing treatments. It is based on the inhibition of Hyaluronan (HA), a structural polysaccharide that plays a role in the signaling pathway that leads to the onset of airway diseases. Such inhibition blocks the development of airway inflammation and airway hyperresponsiveness (AHR), two of the components associated with airway diseases, and thus may be useful in the treatment of such diseases. The invention discloses two antagonists of HA, i.e. heparosan, and Hyaluronan oligosaccharides (oHAs). Their administration to a human subject in need can be accomplished via the use of an inhaler or nebulizer.
Commercial Applications
  • Effective treatment of airway diseases
Competitive Advantages
  • Potentially cost-effective treatment for airway diseases, with higher specificity and reduced side effect as compared to existing treatments

Request More Info

Licensing Contact: